While there is currently no cure for geographic atrophy, certain treatments, such as complement inhibitors, can help slow its progression by targeting immune system activity that damages the macula.

FDA Fast Track designation has been granted to CTx001 for Geographic Atrophy secondary to Age-related Macular Degeneration CTx001 is an investigational AAV-based gene therapy designed to modulate ...

There is currently no cure for geographic atrophy (GA) – in other words, no effective therapy to entirely halt the disease process, restore vision or reverse the damage to the retina. Currently ...

LONG BEACH, Calif. -- Concomitant treatment with drugs for geographic atrophy (GA) and neovascular macular degeneration (nAMD) appeared to have no major safety issues or significantly affect either ...

SOUTH SAN FRANCISCO, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Today, Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing novel therapies for patients with ...

While pivotal research on therapies for neovascular age-related macular degeneration (nAMD) and geographic atrophy (GA) focused on one condition or the other, retina specialists commonly encounter ...

CTx001 is an investigational AAV-based gene therapy designed to modulate multiple pathways of the complement system Opti-GAIN is a first-in-human trial to evaluate the safety, tolerability, and ...

What is Geographic Atrophy (GA)?Geographic Atrophy is a late-stage form of dry age-related macular degeneration (AMD) that causes progressive damage to the macula, the central area of the retina.

Geographic atrophy is an eye condition that can severely impact a person’s vision, which can affect their routine and independence. Once a person develops geographic atrophy, it cannot be reversed and ...

Steffen Schmitz-Valckenberg, MD, discusses how optical coherence tomography-based models may enable rapid, noninvasive assessment of functional loss in GA at Angiogenesis 2026.